Clinical data | |
---|---|
Pronunciation | Curosurf, Survanta, others |
Other names | Beractant, Poractant alfa, others |
AHFS/Drugs.com | Monograph |
License data | |
ATC code | |
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII |
Pulmonary surfactant is used as a medication to treat and prevent respiratory distress syndrome in newborn babies.[1]
Prevention is generally done in babies born at a gestational age of less than 32 weeks.[1] It is given by the endotracheal tube.[1] Onset of effects is rapid.[2] A number of doses may be needed.[2]
Side effects may include slow heart rate and low oxygen levels.[1] Its use is also linked with intracranial bleeding.[1] Pulmonary surfactant may be isolated from the lungs of cows or pigs or made artificially.[1][3][4]
Pulmonary surfactant was discovered in the 1950s and a manufactured version was approved for medical use in the United States in 1990.[3] It is on the World Health Organization's List of Essential Medicines.[5]